Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients

Clinical Therapeutics

Volumn 36, Issue 5, 2014, Pages 737-747

  Tkacz, Joseph ^a   Ellis, Lorie ^b   Bolge, Susan C ^b   Meyer, Roxanne ^b   Brady, Brenna L ^a   Ruetsch, Charles ^a  

^a Health Analytics LLC   (United States)

^b Janssen Scientific Affairs LLC   (United States)

Author keywords

adalimumab; adherence; claims data; etanercept; golimumab; pharmacoeconomic

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CEREBROVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CHRONIC PAIN; COMORBIDITY; DEPRESSION; DISORDERS OF LIPID METABOLISM; DRUG USE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OSTEOARTHRITIS; OUTCOME ASSESSMENT; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; FACTUAL DATABASE; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, CUTANEOUS; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84901456680     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.02.019     Document Type: Article

References (44)

1. A. Gibofsky Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis Am J Manag Care 18 13 Suppl 2012 S295 S302
2. D.L. Scott Biologics-based therapy for the treatment of rheumatoid arthritis Clin Pharmacol Ther 91 2012 30 43
3. Y. Yazici, N. Shi, and A. John Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy Bull NYU Hosp Jt Dis 66 2008 77 85
4. E. Salt, and S.K. Frazier Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature Orthop Nurs 29 2010 260 275
5. J.A. Cramer, A. Roy, and A. Burrell et al. Medication compliance and persistence: terminology and definitions Value Health 11 2008 44 47
6. S. de Achaval, and M.E. Suarez-Almazor Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus Int J Clin Rheumtol 5 2010 313 326
7. A.P. Malaviya, and A.J. Ostor Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept Patient Prefer Adherence 6 2012 589 596
8. P. Li, M.A. Blum, J. Von Feldt, S. Hennessy, and J.A. Doshi Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis Value Health 13 2010 805 812
9. B.J. Borah, X. Huang, V. Zarotsky, and D. Globe Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs Curr Med Res Opin 25 2009 1365 1377
10. O. Brocq, C.H. Roux, and C. Albert et al. TNF-α antagonist continuation rates in 442 patients with inflammatory joint disease Joint Bone Spine 74 2007 148 154
11. Food and Drug Administration. Highlights of Prescribing Information: Humira. 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 125057s0276lbl.pdf. Accessed May 16, 2013.
12. Food and Drug Administration. Enbrel® (etanercept) For Subcutaneous Injection. 2003. http://www.accessdata.fda.gov/drugsatfda-docs/label/2003/ etanimm060503LB.pdf. Accessed May 16, 2013.
13. Food and Drug Administration. Highlights of Prescribing Information: Simponi. 2009. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 125289s000lbl.pdf. Accessed May 16, 2013.
14. S. Dhillon, K.A. Lyseng-Williamson, and L.J. Scott Etanercept: a review of its use in the management of rheumatoid arthritis Drugs 67 2007 1211 1241
15. E.C. Keystone, M.C. Genovese, and L. Klareskog et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study Ann Rheum Dis 68 2009 789 796
16. A. Wiens, C.J. Correr, R. Venson, M.F. Otuki, and R. Pontarolo A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis Rheumatol Int 30 2010 1063 1070
17. H. Zhou, H. Jang, and R.M. Fleischmann et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis J Clin Pharmacol 47 2007 383 396
18. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
19. A.M. Peterson, D.P. Nau, J.A. Cramer, J. Benner, F. Gwadry-Sridhar, and M. Nichol A checklist for medication compliance and persistence studies using retrospective databases Value Health 10 2007 3 12
20. P. Emery, R.M. Fleischmann, and L.W. Moreland et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis Arthritis Rheum 60 2009 2272 2283
21. L.W. Moreland, M.H. Schiff, and S.W. Baumgartner et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial Ann Intern Med 130 1999 478 486
22. M.E. Weinblatt, E.C. Keystone, and D.E. Furst et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum 48 2003 35 45
23. C.I. Coleman, B. Limone, and D.M. Sobieraj et al. Dosing frequency and medication adherence in chronic disease J Manag Care Pharm 18 2012 527 539
24. M. Iskedjian, T.R. Einarson, and L.D. MacKeigan et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis Clin Ther 24 2002 302 316
25. S.D. Saini, P. Schoenfeld, K. Kaulback, and M.C. Dubinsky Effect of medication dosing frequency on adherence in chronic diseases Am J Manag Care 15 2009 e22 e33
26. A.L. Granger, S.E. Fehnel, S.L. Hogue, L. Bennett, and H.M. Edin An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey J Affect Disord 90 2006 217 221
27. D. Kendler, A.W. Kung, and H. Fuleihan Gel et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate Maturitas 48 2004 243 251
28. J.Y. Reginster, V. Rabenda, and A. Neuprez Adherence, patient preference and dosing frequency: understanding the relationship Bone 38 4 Suppl 1 2006 S2 S6
29. X. Gao, D.P. Nau, S.A. Rosenbluth, V. Scott, and C. Woodward The relationship of disease severity, health beliefs and medication adherence among HIV patients AIDS Care 12 2000 387 398
30. A. Pasma, A. van't Spijker, J.M. Hazes, J.J. Busschbach, and J.J. Luime Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review Semin Arthritis Rheum 43 2013 18 28
31. T. Koncz, M. Pentek, V. Brodszky, K. Ersek, E. Orlewska, and L. Gulacsi Adherence to biologic DMARD therapies in rheumatoid arthritis Expert Opin Biol Ther 10 2010 1367 1378
32. M.R. DiMatteo, P.J. Giordani, H.S. Lepper, and T.W. Croghan Patient adherence and medical treatment outcomes: a meta-analysis Med Care 40 2002 794 811
33. I. Contreras-Yanez, S. Ponce De Leon, J. Cabiedes, M. Rull-Gabayet, and V. Pascual-Ramos Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs Am J Med Sci 340 2010 282 290
34. V. Pascual-Ramos, I. Contreras-Yanez, A.R. Villa, J. Cabiedes, and M. Rull-Gabayet Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability Arthritis Res Ther 11 2009 R26
35. B. Tang, M. Rahman, H.C. Waters, and P. Callegari Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis Clin Ther 30 2008 1375 1384
36. F. Viller, F. Guillemin, S. Briancon, T. Moum, T. Suurmeijer, and W. van den Heuvel Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study J Rheumatol 26 1999 2114 2122
37. A. Garcia-Gonzalez, M. Richardson, and M. Garcia Popa-Lisseanu et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus Clin Rheumatol 27 2008 883 889
38. E.L. Williams, and C.J. Edwards Patient preferences in choosing anti-TNF therapies-R1 Rheumatology (Oxford) 45 2006 1575 1576
39. M. Jeffery, A. Stokes, K. Johnson, D. Anderson, and B. Harper Patient Preferences for Tumor Necrosis Factor (TNF) Antagonist 2004 The Research Partnership Ltd, Rheumatology Research International London, UK
40. V. Modena, G. Bianchi, and D. Roccatello Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev 12 2013 835 838
41. G. van der Velde, B. Pham, and M. Machado et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review Arthritis Care Res (Hoboken) 63 2011 65 78
42. N.V. Chawla, and D.A. Davis Bringing big data to personalized healthcare: a patient-centered framework J Gen Intern Med 28 Suppl 3 2013 S660 S665
43. P.T. Tyree, B.K. Lind, and W.E. Lafferty Challenges of using medical insurance claims data for utilization analysis Am J Med Qual 21 2006 269 275
44. S. Ramiro, P. Machado, J.A. Singh, R.B. Landewe, and J.A. da Silva Applying science in practice: the optimization of biological therapy in rheumatoid arthritis Arthritis Res Ther 12 2010 220